secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019877
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote
--------------------------------------------------------------------------------

- Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).
- Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.
- Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.
- DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.
- Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/0001493152-24-019877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer